Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 39
Semaglutide resolves MASLD inflammation
A 2026 meta-analysis of 10 trials found semaglutide resolved steatohepatitis and cut liver fat in MASLD patients, but fibrosis improvement was not significant.
Semaglutide and menstrual changes
Semaglutide users report heavier periods and cycle shifts. Here is what safety data and clinical research say about GLP-1 agonists and menstruation.
Semaglutide eased RLS in Parkinson's case
A 2026 case report found that semaglutide improved treatment-resistant restless legs syndrome in one Parkinson's disease patient. The finding is preliminary.
Semaglutide below max dose: real-world data
A Slovak observational study found 11.35% mean weight loss at six months on submaximal semaglutide doses. Below trial figures, but clinically relevant.
Who loses less weight on semaglutide?
A 163-patient retrospective study links diabetes, age over 60, and Hispanic ethnicity to lower weight loss on semaglutide at 12 months.
Most statin label warnings lack evidence
A 2026 Lancet meta-analysis found only 4 of 66 listed statin side effects are backed by trial evidence. What GLP-1 users should know.
Greener route to tirzepatide synthesis
A 2026 JACS study combines tag-assisted synthesis with selenoester ligation to assemble peptide drugs up to 39 residues long using far less solvent.
TB-500 and Flexibility: What We Know
Community users report flexibility gains on TB-500. The preclinical mechanism is plausible, but no human study has measured it. Here is the full picture.
Tirzepatide and metformin for PCOS: RCT
A 60-patient Chinese trial found tirzepatide 5 mg plus metformin cut weight by 10.4 kg in 16 weeks for women with PCOS, six times more than metformin alone.
TOGETHER-PsA: tirzepatide plus ixekizumab
A Phase 3b trial finds that adding tirzepatide to ixekizumab improves joint disease and weight in psoriatic arthritis patients with obesity.
GLP-1 drugs in teens: what youth say
A qualitative study of 29 adolescents on GLP-1 and other weight-loss drugs finds families are positive about treatment but uncertain about when to stop.
Peptide blood work: which labs to request
IGF-1, fasting glucose, HbA1c, lipid panel, CMP, CBC, and thyroid markers. Here is what each one tracks and why your clinician may want it.